The effect of striatal pre‐enkephalin overexpression in the basal ganglia of the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson's disease

The midbrain dopamine (DA) cell death underlying Parkinson's disease (PD) is associated with upregulation of pre‐enkephalin (pENK) in striatopallidal neurons. Our previous results obtained with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) parkinsonian monkeys suggest that increased striatal expression of pENK mRNA is a compensatory mechanism to alleviate PD‐related motor symptoms. In this study, we tested the hypothesis that increased pENK expression in the striatum protects against the neurotoxic insults of MPTP in mice. To this end, recombinant adeno‐associated virus serotype 2 also containing green fluorescent protein was used to overexpress pENK prior to DA depletion. Our results showed that overexpression of pENK in the striatum of MPTP mice induced: (i) increased levels of the opioid peptide enkephalin (ENK) in the striatum; (ii) higher densities of ENK‐positive fibers in both the globus pallidus (GP) and the substantia nigra; (iii) higher locomotor activity; and (iv) a higher density of striatal tyrosine hydroxylase‐positive fibers in the striatum. In addition, striatal overexpression of pENK in MPTP ‐treated mice led to 52 and 43% higher DA concentrations and DA turnover, respectively, in the GP compared to sham‐treated MPTP mice. These observations are in agreement with the idea that increased expression of pENK at an early stage of disease can improve PD symptoms.

[1]  F. Zhou,et al.  Supersensitive presynaptic dopamine D2 receptor inhibition of the striatopallidal projection in nigrostriatal dopamine-deficient mice. , 2013, Journal of neurophysiology.

[2]  S. Hébert,et al.  Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease , 2013, PloS one.

[3]  Robert E. Burke,et al.  Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.

[4]  G. Drolet,et al.  Enkephalin knockdown in the central amygdala nucleus reduces unconditioned fear and anxiety , 2013, The European journal of neuroscience.

[5]  J. Cloutier,et al.  Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease , 2013, Genes, brain, and behavior.

[6]  E. Bézard,et al.  Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies , 2013, Movement disorders : official journal of the Movement Disorder Society.

[7]  S. Duty,et al.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease , 2011, British journal of pharmacology.

[8]  O. Mabrouk,et al.  The globus pallidus (GP) is a critical nucleus along the indirect pathway of the basal ganglia (BG) and a known contributor to sensorimotor regulation (for a review, see , 2011 .

[9]  L. Reichardt,et al.  TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons , 2011, Proceedings of the National Academy of Sciences.

[10]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[11]  Stephen M. Johnson,et al.  Protecting motor networks during perinatal ischemia: the case for delta‐opioid receptors , 2010, Annals of the New York Academy of Sciences.

[12]  Douglas Wahlsten,et al.  The precision of video and photocell tracking systems and the elimination of tracking errors with infrared backlighting , 2010, Journal of Neuroscience Methods.

[13]  F. Cicchetti,et al.  Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  A. Benazzouz,et al.  Intrapallidal injection of 6-hydroxydopamine induced changes in dopamine innervation and neuronal activity of globus pallidus , 2009, Neuroscience.

[15]  S. Fowler,et al.  Striatal Expression of a Calmodulin Fragment Improved Motor Function, Weight Loss, and Neuropathology in the R6/2 Mouse Model of Huntington's Disease , 2009, The Journal of Neuroscience.

[16]  R. Burke,et al.  Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.

[17]  F. Cicchetti,et al.  Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions , 2009, Journal of neurochemistry.

[18]  D. Surmeier,et al.  Calcium homeostasis, selective vulnerability and Parkinson's disease , 2009, Trends in Neurosciences.

[19]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[20]  Ole Isacson,et al.  Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.

[21]  J. Wang,et al.  Axonal Degeneration of Nigra-striatum Dopaminergic Neurons Induced by 1-Methyl-4-phenyl-1,2,3, 6-tetrahydropyridine in Mice , 2009, The Journal of international medical research.

[22]  G. Miller,et al.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice , 2007, Proceedings of the National Academy of Sciences.

[23]  Xiang-rui Wang,et al.  Dose-dependent neuroprotection of delta opioid peptide [d-Ala2, d-Leu5] enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats , 2007, Neuroscience Letters.

[24]  Xi Chen,et al.  Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.

[25]  P. Bédard,et al.  Opioids and motor complications in Parkinson's disease. , 2006, Trends in pharmacological sciences.

[26]  Bernardino Ghetti,et al.  Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.

[27]  A. Sampson,et al.  Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models , 2006, Nature Neuroscience.

[28]  L. Grégoire,et al.  Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys , 2005, Neuropharmacology.

[29]  M. Block,et al.  Microglial NADPH Oxidase Mediates Leucine Enkephalin Dopaminergic Neuroprotection , 2005, Annals of the New York Academy of Sciences.

[30]  Ying Xia,et al.  Oxygen-sensitive {delta}-opioid receptor-regulated survival and death signals: novel insights into neuronal preconditioning and protection. , 2005, The Journal of biological chemistry.

[31]  U. Barry,et al.  Opioids: old drugs for potential new applications. , 2005, Current pharmaceutical design.

[32]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ilya Bezprozvanny,et al.  Deranged neuronal calcium signaling and Huntington disease. , 2004, Biochemical and biophysical research communications.

[34]  E. Butelman,et al.  Effect of the κ opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice , 2004, Psychopharmacology.

[35]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[36]  E. Bézard,et al.  Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei , 2003, Neurobiology of Disease.

[37]  G. Miller,et al.  Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2002, Experimental Neurology.

[38]  W. Hauswirth,et al.  Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.

[39]  J. Langston,et al.  Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey , 2002, Neuroscience.

[40]  H. Akil,et al.  Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems , 2002, The Journal of comparative neurology.

[41]  J. Brotchie,et al.  Antiparkinsonian Action of a δ Opioid Agonist in Rodent and Primate Models of Parkinson's Disease , 2001, Experimental Neurology.

[42]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[43]  E. Bézard,et al.  Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys , 2001, Neurobiology of Disease.

[44]  T. Su,et al.  Delta Opioid Peptide Augments Functional Effects and Intrastriatal Graft Survival of Rat Fetal Ventral Mesencephalic Cells , 2001, Cell transplantation.

[45]  Martin Lévesque,et al.  Organization of the basal ganglia: the importance of axonal collateralization , 2000, Trends in Neurosciences.

[46]  D. Lévesque,et al.  Contrasting Patterns and Cellular Specificity of Transcriptional Regulation of the Nuclear Receptor Nerve Growth Factor‐Inducible B by Haloperidol and Clozapine in the Rat Forebrain , 2000, Journal of neurochemistry.

[47]  J. Bolam,et al.  Synaptic organisation of the basal ganglia , 2000, Journal of anatomy.

[48]  T. Su,et al.  Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons , 2000 .

[49]  W. Hauber,et al.  Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat , 1999, Behavioural Brain Research.

[50]  T. Di Paolo,et al.  Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists , 1999, Journal of neurochemistry.

[51]  D. Peckys,et al.  Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study , 1999, Neuroscience.

[52]  A. Gingras,et al.  μ-Opioid Receptor Activates Signaling Pathways Implicated in Cell Survival and Translational Control* , 1998, The Journal of Biological Chemistry.

[53]  O. Hornykiewicz.  Biochemical aspects of Parkinson's disease , 1998, Neurology.

[54]  A. Björklund,et al.  L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.

[55]  H. Akil,et al.  Endogenous opioids: overview and current issues. , 1998, Drug and alcohol dependence.

[56]  W. Hauber,et al.  The effects of globus pallidus lesions on dopamine-dependent motor behaviour in rats , 1998, Neuroscience.

[57]  A. Crossman,et al.  Kappa‐opioid receptor agonists increase locomotor activity in the monoamine‐depleted rat model of parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[58]  M. Chesselet,et al.  Basal ganglia and movement disorders: an update , 1996, Trends in Neurosciences.

[59]  J. Brotchie,et al.  On the Role of Enkephalin Cotransmission in the GABAergic Striatal Efferents to the Globus Pallidus , 1994, Experimental Neurology.

[60]  C. Marsden,et al.  Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus , 1985, Neuroscience.

[61]  K. Yoshikawa,et al.  Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system. , 1984, The Journal of biological chemistry.

[62]  S. Spampinato,et al.  Opioid Receptors , 2015, Methods in Molecular Biology.

[63]  D. Swaab,et al.  Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment. , 2013, Restorative neurology and neuroscience.

[64]  Ying Xia,et al.  δ-Opioid receptor activation attenuates oxidative injury in the ischemic rat brain , 2009, BMC Biology.

[65]  R. Llinás,et al.  Disturbed Ca 2 signaling and apoptosis of medium spiny neurons in Huntington ’ s disease , 2005 .

[66]  E. Butelman,et al.  Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. , 2004, Psychopharmacology.

[67]  W. Hauber,et al.  Dopaminergic innervation of the rat globus pallidus characterized by microdialysis and immunohistochemistry , 2003, Experimental Brain Research.

[68]  J T Williams,et al.  Cellular and synaptic adaptations mediating opioid dependence. , 2001, Physiological reviews.

[69]  J. Brotchie,et al.  Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. , 2001, Experimental neurology.

[70]  Y. Smith,et al.  Microcircuitry of the direct and indirect pathways of the basal ganglia. , 1998, Neuroscience.

[71]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.